Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies

Leuk Lymphoma. 2015 Jan;56(1):226-9. doi: 10.3109/10428194.2014.910657. Epub 2014 Jun 17.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Azacitidine / pharmacology*
  • Biphenyl Compounds / pharmacology*
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
  • Cell Line, Tumor
  • Humans
  • Leukemia, Myeloid / metabolism
  • Nitrophenols / pharmacology*
  • Piperazines / pharmacology
  • Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Sulfonamides / pharmacology*

Substances

  • ABT-737
  • Antineoplastic Agents
  • Biphenyl Compounds
  • Bridged Bicyclo Compounds, Heterocyclic
  • Nitrophenols
  • Piperazines
  • Proto-Oncogene Proteins c-bcl-2
  • Sulfonamides
  • Azacitidine
  • venetoclax